PortViewPortView
VYLD logo

Inverse VIX Short-Term Futures ETNs due March 22, 2045 (VYLD) ETF Holdings & Analysis

ETFOther

$30.84+0.37%
1-year price historyRange $25.94 – $30.86
52-week range$30.84
$25.94$30.86

What VYLD does

This investment product is engineered to reflect the daily performance of the S&P500 VIX Short-Term Futures Points-Change Inverse Daily Index. The benchmark itself measures the day-to-day value changes resulting from maintaining a continuously updated short position in VIX futures contracts, which are traded on the Cboe Futures Exchange. Consequently, these notes are intended for investors who anticipate the value of this particular inverse index to rise during their ownership period, thereby generating a positive return.

Fund profile

Category
Other
AUM
$2.97M
52-week high
$30.86
52-week low
$25.94

PortView Portfolio Insights

PortView analyzes how VYLD fits your actual portfolio — position weight, ETF overlap with your other funds, sector and geographic exposure, concentration, and how this fund contributes to your portfolio risk and return. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze VYLD in PortView →

Related securities

Related stocks

Frequently asked questions

What does VYLD track?
VYLD is the Inverse VIX Short-Term Futures ETNs due March 22, 2045, a Other ETF.
What is the expense ratio of VYLD?
Expense ratio data for VYLD is shown on the page when available from our data provider.
What are the largest holdings in VYLD?
VYLD's top holdings are listed on this page when available.
How can PortView analyze VYLD overlap with other ETFs?
PortView computes the holdings overlap between VYLD and the other ETFs and stocks you own, plus your combined sector and geographic exposure, so you can see true diversification.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.